814 PATENT ABSTRACTS

Val-Gly-Ala-Pro-Leu-Pro-Leu-Leu-Glu-Glu- Val-Pr o-Pro-Trp-Thr-Gly-Glu-Val-A n-Pro of the composition Asp/Asn 14, Thr 3, Ser 15, Glu/Gln 12, Pro 10, Gly 12, Ala 10, Val 7, Met 4, Ile 1, Leu 15, Tyr 2, Phe 3, Lys 4, His 2, Arg 10, Trp 2, a molecular weight of 13000 Dalton and an isoelectric point I.P. of 6 to 6.5. The peptide hormone, as well as its C-terminal fragments ob- tained after partial cyanogen bromide fission between and behind Met groups, possess a high relaxing action on the smooth bloodvessel musculature.

4752471

C A N C E R D E T E C T I O N P R E P A R A T I O N S A N D M E T H O D

Jack Makari

A method for detecting cancer comprises intra- dermally injecting into a patient a test prepara- tion comprising a glycoprotein-polysaccharide- like antigenic substance admixed with the patient's blood serum. The patient's serum is also injected intradermally as a control and the physical dimensions of the erythemas of the in- jections measured and compared as an indica- tion of the presence of cancer. An initial antigenic substance is derived from cancerous tissues by disintegrating the tissue to enable the separation of the nuclei and cell membranes from the mitochondrial fraction of the cell. After lipids are removed from the mitochondrial frac- tion, it is hydrolyzed in hot alkali, dialyzed and then deproteinated. The cancer specificity of the antigenic substance is enhanced by gel filtration. Prior to admixture with the antigenic substance, the blood serum is subjected to an adsorptive procedure to remove non:cancerous antibodies which might otherwise be rea'ctiye with the anti- genic substance. A proteolytic'enzyme (e.g. trypsin) is added to a portion of the blood serum to provide, in the preferred embodiment, addi- tional cancer detection preparations.

4752473

E X P R E S S I O N O F G L Y C O S Y L A T E D H U M A N

I N F L U E N Z A H E M A G G L U T I N I N P R O T E I N S

Debi Nayak, M Abdu Jabbar assigned to The Regents of the University of California

Glycosylated polypeptides corresponding to antigenic portions of mature human influenza

hemaggiutinin are microbially produced in S. cerevisiae. The glycosylated polypeptides are ef- fective as vaccination agents, since the glycosylated polypeptides closely minic the naturally occurring mature influenza hemag- glutinin which is also glycosylated.

4752474

L I V E R A B I E S V A C C I N E

Lothar Schneider, D 6230 Frankfurt am Main 80, Federal Republic Of Germany

A process for the preparation of a live rabies vac- cine for the oral vaccination of Canidae is described. Special variants of the SAD rabies virus strain, called variant strain VAI, VAI2, VAI7 and VA20, are propagated in the BSR-19 cell line and processed in a known manner to give a vaccine which is effective on oral administra- tion to foxes and dogs.

4752475

C O M P O S I T I O N S F O R T H E C O N T R O L O F C O C C I D I O S I S I N

P O U L T R Y

Paul J Davis, James F Reynolds, Bedfordshire, United Kingdom assigned to Unilever Patent Holdings B V

Essentially solid free-flowing pre-mixes and aqueous concentrates intended for addition to nutrient material in the manufacture of feed- stuffs for poultry are provided consisting essen- tially of from about 1000 to about 1,000,000 viable sporulated oocysts of at least one species of coccidia to which poultry are susceptible and at least one edible thickening agent.

4752569

S I A L Y L A T E D L E W I S X E P I T O P E , A N T I B O D I E S A N D D I A G N O S I S

Paul I Terasaki, Masaki Hirota, Kiyoyasu Fukushima, Akemi Wakisaka, Takashi Iguro assigned to The Regents of the University of California

Detection of sialylated Lewisx antigen in sera is employed as diagnostic of the presence of cancer. Conveniently, monoclonal antibodies are pro-

PATENT ABSTRACTS

vided which are shown to be useful in the dia- gnosis of a neoplastic condition, with a wide variety of different tumors. The hybridoma CSLEX1 was deposited at the A.T.C.C. on June 20, 1984 and given Accession No. HB8580.

4752582

M O N O C L O N A L A N T I B O D I E S T O H U M A N G L Y C O P H O R I N A A N D

C E L L L I N E S F O R T H E P R O D U C T I O N T H E R E O F

Marti Vanderlaan, William Bigbee, Ronald Jensen, Stella S Fong, Richard G Langlois as- signed to The United States of America as represented by the United States Department of Energy

Cloned mouse hybridoma cell lines have been established which continuously produce anti- bodies that are highly specific to and exhibit high affinity for glycophorin AN and differentiate between the M and N forms of human glycophorin A.

4752583

M O N O C L O N A L A N T I B O D I E S T O H U M A N H E M O G L O B I N S A N D

C E L L L I N E S F O R T H E P R O D U C T I O N T H E R E O F

Ronald H Jensen, Marti Vanderlaan, William Bigbee, Larry Stanker, Elbert W Branscomb, Robert Grabske assigned to The United States of America as represented by the United States Department of Energy

The present invention provides monoclonal antibodies specific to and distinguish between hemoglobin S and hemoglobin A and methods for their production and use. These antibodies are capable of distinguishing between two hemoglobin types which differ from each other by only a single amino acid residue. The anti- bodies produced according to the present method are useful as immunofluorescent mar- kers to enumerate circulating red blood cells which have the property of altered expression of the hemoglobin gene due to somatic mutation in

815

stem cells. Such a measurement is contemplated as an assay for in vivo cellular somatic mutations in humans. Since the monoctonal antibodies produced in accordance with the instant inven- tion exhibit a high degree of specificity to and greater affinity for hemoglobin S, they are suitable for labeling human red blood cells for flow cytometric detection of hemoglobin genotype.

4752585

O X I D A T I O N - R E S I S T A N T M U T E I N S

Kirston E Koths, Robert Halenbeck, Michael A Innis, Alice M Wang, Ze'E Shaked assigned to Cetus Corporation

A biologically active reference therapeutic pro- tein is protected against oxidation by a method involving substituting a conservative amino acid for each methionyl residue susceptible to chloramine T or peroxide oxidation, wherein ad- ditional, non-susceptible methionyl residues are not so substituted. The oxidation-resistant mutein so produced is preferably a ,human mutein of interleukin-2 or interferon- beta, and the conservative amino acid is most preferably alanine.

4752601

M E T H O D O F B L O C K I N G I M M U N E C O M P L E X B I N D I N G T O

I M M U N O G L O B U L I N FC R E C E P T O R S

Gary Hahn assigned to Immunetech Pharma- ceuticals

A method of modulating immune complex mediated immune responses in mammals is described, comprising administering a peptide comprising the amino acid sequence See Patent for Tabular Presentation PS Specific uses in reducing immune complex mediated inflamma- tion or tissue destruction and in modulating the proliferation or function of mononuclear cells are disclosed.